# OptiTROP-Lung03 (NCT05631262)

> SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors

No report yet. It can be ordered.

- Drugs tested: sacituzumab tirumotecan
- Indication: advanced solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05631262
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Conditions: Selected Subjects With Advanced Solid Tumors
- Interventions: SKB264; Docetaxel
- Enrollment: 321
- Primary outcome: Objective Response Rate (ORR)
- Primary outcome: Incidence and severity of adverse events (AEs)

## Indexed commentary on OptiTROP-Lung03 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=optitrop-lung03-nct05631262

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05631262", "email": "<work email>"}; the inbox owner confirms by the emailed link.